Intercept Pharmaceuticals Restructures with 146 Layoffs Following Ocaliva Withdrawal
SOURCENews reportView the filing ↗
What we know
Based on news reporting.
Summary
Intercept Pharmaceuticals has announced a restructuring that will result in 146 layoffs, following the withdrawal of its drug Ocaliva. This decision comes as the company seeks to realign its operations after the setback with Ocaliva, which has impacted its business strategy. The layoffs are part of a broader effort to streamline the organization and focus on future growth opportunities. The exact locations and departments affected by these layoffs have not been disclosed. This move reflects the challenges faced by Intercept in the current pharmaceutical landscape.
Intercept Pharmaceuticals cut 146 jobs as of December 17, 2025.
That is roughly 73% of the 200 people Intercept Pharmaceuticals employs.
LayoffTalk has tracked 3 layoff events at Intercept Pharmaceuticals since December 2025, including 146 jobs documented in official WARN filings, with 2 additional events known from news reporting.
Comments (0)
Anonymous by default. Be kind — people reading this may be going through it right now.
No comments yet. Be the first to share your thoughts.
Affected by this?
Share your story anonymously — it helps others reading this feel less alone.
Share your story →More layoffs at Intercept Pharmaceuticals
Recent tracked events at this company.